The Pancreatic Surgery Service, Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.
Reprints: Matthew HG Katz, MD, FACS, Chief, Pancreatic Surgery Service, Associate Professor, Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, 1400 Pressler Street, FCT 17.6058, Unit #1484, Houston, TX 77030-4009. E-mail: email@example.com.
Editorial to accompany publication of: “Oncologic benefits of neoadjuvant chemoradiation with gemcitabine versus upfront surgery in patients with borderline resectable pancreatic cancer: a prospective, randomized, open-label, multicenter phase 2/3 trial” by Choi and colleagues.
The authors declare no conflicts of interest.